Background Background Patients with
Patients with schizophrenia have an increased risk of schizophrenia have an increased risk of developing diabetes.However, no developing diabetes.However, no pragmatic pathway of care has ever been pragmatic pathway of care has ever been proposed in order to identify individuals at proposed in order to identify individuals at risk and manage that risk effectively. risk and manage that risk effectively.
Aims Aims To develop practical
To develop practical recommendations for the screening and recommendations for the screening and management of diabetes in schizophrenia. management of diabetes in schizophrenia.
Method Method Staged review of evidence for
Staged review of evidence for the underrecognition of diabetesin people the underrecognition of diabetesin people with schizophrenia and of the applicability with schizophrenia and of the applicability of current screening strategies to this of current screening strategies to this population.Recommendations for pragpopulation.Recommendations for pragmatic pathways of care were developed. matic pathways of care were developed.
Results

Results All patients with schizophrenia
All patients with schizophrenia should be screened and managed as a should be screened and managed as a high-risk group for the development of high-risk group for the development of diabetes. Psychiatrists should be diabetes.Psychiatrists should be responsible for screening and diabetes risk responsible for screening and diabetes risk management; primary care physicians management; primary care physicians and/or diabetologists should be and/or diabetologists should be responsible for managing diabetes.Choice responsible for managing diabetes.Choice of antipsychotics should be based on of antipsychotics should be based on achieving good control of schizophrenia, achieving good control of schizophrenia, which may improve compliance with which may improve compliance with diabetes risk reduction strategies. diabetes risk reduction strategies.
The prevalence of diabetes mellitus in The prevalence of diabetes mellitus in developing countries and throughout the developing countries and throughout the Westernised world is increasing dramatiWesternised world is increasing dramatically, with estimates suggesting a doubling cally, with estimates suggesting a doubling in prevalence over the next 10 years. In in prevalence over the next 10 years. In 1997, an estimated 124 million people 1997, an estimated 124 million people worldwide had diabetes, of whom 97% worldwide had diabetes, of whom 97% had type 2 diabetes (Amos had type 2 diabetes (Amos et al et al, 1997) . In , 1997). In the UK alone at least 1.4 million people the UK alone at least 1.4 million people have been diagnosed with type 2 diabetes have been diagnosed with type 2 diabetes (Diabetes UK, 2002) , and it has been (Diabetes UK, 2002) , and it has been estimated that 221 million people around estimated that 221 million people around the world will have the condition by 2010 the world will have the condition by 2010 (Amos (Amos et al et al, 1997) . The reasons for this , 1997). The reasons for this substantial and deepening burden of type substantial and deepening burden of type 2 diabetes in the general population are 2 diabetes in the general population are complex, but include the increasing prevacomplex, but include the increasing prevalence of adult and childhood obesity, lence of adult and childhood obesity, unhealthy diets, sedentary lifestyles and a unhealthy diets, sedentary lifestyles and a steadily ageing population. steadily ageing population.
The prevalence of diabetes among The prevalence of diabetes among people with schizophrenia may be two to people with schizophrenia may be two to four times higher than in the general popufour times higher than in the general population (Keskiner lation (Keskiner et al et al, 1973; Mukherjee , 1973; Mukherjee et al et al, , 1996; Dixon 1996; Dixon et al et al, 2000; Sernyak , 2000; Sernyak et al et al, 2002; , 2002; Lindenmayer Lindenmayer et al et al, 2003; Subramaniam , 2003; Subramaniam et al et al, , 2003 ). Schizophrenia appears to be an 2003). Schizophrenia appears to be an independent risk factor for diabetes independent risk factor for diabetes (Henderson, 2002; Ryan & Thakore, (Henderson, 2002; Ryan & Thakore, 2002) , and many individuals with schizo-2002) , and many individuals with schizophrenia have a family history of the condiphrenia have a family history of the condition (Dynes, 1969; Mukherjee tion (Dynes, 1969; Mukherjee et al et al, 1989; , 1989; Cheta Cheta et al et al, 1990) . A genetic predisposition , 1990) . A genetic predisposition to diabetes appears to be unmasked by the to diabetes appears to be unmasked by the many poor health behaviours associated many poor health behaviours associated with schizophrenia, including an unhealthy with schizophrenia, including an unhealthy diet, a lack of exercise and a tendency to diet, a lack of exercise and a tendency to smoke (Brown smoke (Brown et al et al, 1999) . , 1999). The part played by antipsychotic The part played by antipsychotic medications in the development of diabetes medications in the development of diabetes is controversial. Recent data from placebois controversial. Recent data from placebocontrolled studies in patients with schizocontrolled studies in patients with schizophrenia have shown that the incidence of phrenia have shown that the incidence of diabetes is similar in placebo and drug diabetes is similar in placebo and drug cohorts (Cunningham cohorts (Cunningham et al et al, 2003; Sowell , 2003; Sowell et al et al, 2003) . Some commentators suggest , 2003) . Some commentators suggest that the risk of blood glucose abnormalities that the risk of blood glucose abnormalities may be higher with the atypical may be higher with the atypical antipsychotic medications than the typical antipsychotic medications than the typical antipsychotic medications (Sernyak antipsychotic medications (Sernyak et al et al, , 2002; Cunningham 2002; Cunningham et al et al, 2003) , but such , 2003), but such conclusions seem to be premature. To date, conclusions seem to be premature. To date, it has not been possible within studies to it has not been possible within studies to adjust for levels of adherence to medication adjust for levels of adherence to medication or to control for important confounders or to control for important confounders such as age, ethnicity or family history. In such as age, ethnicity or family history. In addition, none of the studies provides data addition, none of the studies provides data on the number of patients in each cohort on the number of patients in each cohort who were screened for glycaemic abnorwho were screened for glycaemic abnormalities, which is another important malities, which is another important confounder when attempting to assess the confounder when attempting to assess the prevalence of diabetes within populations. prevalence of diabetes within populations.
At present, therefore, any guidelines for At present, therefore, any guidelines for the screening and management of type 2 the screening and management of type 2 diabetes in individuals with schizophrenia diabetes in individuals with schizophrenia should be based on the premise that type should be based on the premise that type 2 diabetes (and most probably impaired 2 diabetes (and most probably impaired glucose tolerance) is more common in glucose tolerance) is more common in patients with schizophrenia, and that all patients with schizophrenia, and that all antipsychotic medications may have an antipsychotic medications may have an effect on glucose tolerance. effect on glucose tolerance.
METHOD METHOD
In order to develop pragmatic solutions for In order to develop pragmatic solutions for the screening and management of diabetes the screening and management of diabetes in patients with schizophrenia, a staged in patients with schizophrenia, a staged review process was adopted, using the review process was adopted, using the evidence currently available in the literaevidence currently available in the literature, the standards set out in the National ture, the standards set out in the National Service Framework (NSF) for Diabetes Service Framework (NSF) for Diabetes (Department of Health, 2002) , (Department of Health, 2002) (2000, 2002) . The first stage Diabetes UK (2000, 2002) . The first stage of the review involved an overview of the of the review involved an overview of the prevalence of diabetes mellitus in both the prevalence of diabetes mellitus in both the general population and in people with general population and in people with schizophrenia, and assessed the numbers schizophrenia, and assessed the numbers of patients likely to be undiagnosed and of patients likely to be undiagnosed and who might benefit from a screening stratwho might benefit from a screening strategy. Stage two reviewed the screening proegy. Stage two reviewed the screening process in terms of who should be screened, cess in terms of who should be screened, how screening should be undertaken, and how screening should be undertaken, and who should take responsibility for any who should take responsibility for any screening. Finally, recommendations were screening. Finally, recommendations were developed for pragmatic pathways of care developed for pragmatic pathways of care in individuals with schizophrenia at risk in individuals with schizophrenia at risk of developing diabetes. of developing diabetes.
RESULTS RESULTS
Screening for diabetes Screening for diabetes
Studies in the UK suggest that in addition to Studies in the UK suggest that in addition to the 1.4 million people who know they have the 1.4 million people who know they have s1 0 6 s1 0 6 et al, 1986; Simmons , 1986; Simmons et al et al, 1991) . Evidence from the UK , 1991). Evidence from the UK Prospective Diabetes Study suggests that Prospective Diabetes Study suggests that type 2 diabetes may begin, on average, 9-12 type 2 diabetes may begin, on average, 9-12 years before the condition is diagnosed (UK years before the condition is diagnosed (UK Prospective Diabetes Study Group, 1995) , Prospective Diabetes Study Group, 1995) , which puts people at great risk of developing which puts people at great risk of developing both macrovascular disease (cardiovascuboth macrovascular disease (cardiovascular, cerebrovascular and peripheral vascular lar, cerebrovascular and peripheral vascular disease) and microvascular complications disease) and microvascular complications (retinopathy and nephropathy). (retinopathy and nephropathy).
B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY
The reasons why so many people with The reasons why so many people with diabetes are unrecognised in the general diabetes are unrecognised in the general population are hard to define. Type 2 population are hard to define. Type 2 diabetes has an insidious onset and is assodiabetes has an insidious onset and is associated with non-specific symptoms (polyuria, ciated with non-specific symptoms (polyuria, polydipsia, nocturia, unexplained weight polydipsia, nocturia, unexplained weight loss, loss of energy, recurrent infections loss, loss of energy, recurrent infections such as candidiasis, and blurred vision) that such as candidiasis, and blurred vision) that could easily be attributed to other causes. could easily be attributed to other causes. This, coupled with the cost and complexity This, coupled with the cost and complexity associated with widespread screening, associated with widespread screening, probably accounts for the 'missing million' probably accounts for the 'missing million' people with diabetes. people with diabetes.
The pre-diabetic state of impaired The pre-diabetic state of impaired glucose tolerance is even more difficult to glucose tolerance is even more difficult to identify, but is of equal if not more concern. identify, but is of equal if not more concern. A number of studies have evaluated the A number of studies have evaluated the progression of this condition to overt type progression of this condition to overt type 2 diabetes, and these studies indicate that 2 diabetes, and these studies indicate that as many as 45% of patients with impaired as many as 45% of patients with impaired glucose tolerance will develop diabetes over glucose tolerance will develop diabetes over a 10-year period (Alberti, 1996; Warram a 10-year period (Alberti, 1996; Warram et al et al, 1996; Meigs , 1996; Meigs et al et al, 2003) . The risk of , 2003) . The risk of developing type 2 diabetes in a high-risk developing type 2 diabetes in a high-risk pre-diabetic population has been reported pre-diabetic population has been reported to to be as high as 35% over 4 years be as high as 35% over 4 years (Knowler (Knowler et al et al, 2002) . , 2002). The hidden nature of diabetes in indiviThe hidden nature of diabetes in individuals with a serious mental illness such as duals with a serious mental illness such as schizophrenia is of major concern, with schizophrenia is of major concern, with studies suggesting that the prevalence of studies suggesting that the prevalence of known diabetes in people with schizoknown diabetes in people with schizophrenia has been grossly underestimated phrenia has been grossly underestimated (Subramaniam (Subramaniam et al et al, 2003) . Active screen-, 2003) . Active screening for impaired glucose tolerance and ing for impaired glucose tolerance and diabetes has found that over 30% of individiabetes has found that over 30% of individuals with schizophrenia may have either duals with schizophrenia may have either one of these conditions, and that the majorone of these conditions, and that the majority of individuals are unaware that they ity of individuals are unaware that they have these problems (Cohn have these problems (Cohn et al et al, 2002 Group, 1998) . Identifying patients as early as poss-1998). Identifying patients as early as possible in the course of their condition -ideally ible in the course of their condition -ideally at the pre-diabetic stage -would allow for at the pre-diabetic stage -would allow for early intervention, a slowing of disease early intervention, a slowing of disease progression, and possibly even a reversal progression, and possibly even a reversal of some of the underlying pathological of some of the underlying pathological changes. However, as can be seen from changes. However, as can be seen from the epidemiological studies, the silent the epidemiological studies, the silent nature of the condition means that the only nature of the condition means that the only way to confidently identify all patients at way to confidently identify all patients at risk of developing diabetes is to use active risk of developing diabetes is to use active population-based screening strategies. population-based screening strategies. Questions remain, however, about who Questions remain, however, about who should be screened, how screening should should be screened, how screening should be undertaken, and who should take be undertaken, and who should take responsibility for screening, both in the responsibility for screening, both in the general population and among those with general population and among those with schizophrenia. schizophrenia.
Who should be screened? Who should be screened? Screening the enScreening the entire population of any country for impaired tire population of any country for impaired glucose tolerance or diabetes would be glucose tolerance or diabetes would be costly and impractical, and it has therefore costly and impractical, and it has therefore been suggested that screening should be been suggested that screening should be focused on high-risk individuals, including focused on high-risk individuals, including those over the age of 40 years and people those over the age of 40 years and people from Black, Asian and minority ethnic from Black, Asian and minority ethnic groups over 25 years groups over 25 years of age with other risk of age with other risk factors (see Appendix).
factors (see Appendix). The relatively recent
The relatively recent recognition that people with severe mental recognition that people with severe mental illnesses such as schizophrenia are at inillnesses such as schizophrenia are at increased risk of developing diabetes suggests creased risk of developing diabetes suggests that these individuals should now also be that these individuals should now also be considered to be in a high-risk group, and considered to be in a high-risk group, and should be included in all national or local should be included in all national or local diabetes screening strategies. diabetes screening strategies.
How should screening be undertaken? How should screening be undertaken? AlAlthough the identification of suitable though the identification of suitable individuals for screening is not entirely individuals for screening is not entirely straightforward, the choice of screening straightforward, the choice of screening technique is even more of an issue. The gold technique is even more of an issue. The gold standard test for diabetes, as endorsed by standard test for diabetes, as endorsed by the World Health Organization (WHO), is the World Health Organization (WHO), is the oral glucose tolerance test (OGTT), the oral glucose tolerance test (OGTT), which requires an overnight fast followed which requires an overnight fast followed by a 75 g glucose drink, with blood samples by a 75 g glucose drink, with blood samples taken for glucose levels before the drink taken for glucose levels before the drink and 2 h afterwards (World Health Organiand 2 h afterwards (World Health Organization, 1999) . A 2 h glucose value of zation, 1999). A 2 h glucose value of 4 411.1 mmol/l is diagnostic of diabetes, 11.1 mmol/l is diagnostic of diabetes, and a value between 7.8 mmol/l and and a value between 7.8 mmol/l and 11.1 mmol/l indicates impaired glucose 11.1 mmol/l indicates impaired glucose tolerance (Table 1) . tolerance (Table 1) .
Although the OGTT is a relatively Although the OGTT is a relatively simple and inexpensive procedure, it is not simple and inexpensive procedure, it is not suitable for use as a high-throughput suitable for use as a high-throughput screening test in most out-patient clinics screening test in most out-patient clinics or primary care surgeries. Following the or primary care surgeries. Following the initial recommendation of the American initial recommendation of the American Diabetes Association (1997), the World Diabetes Association (1997), the World Health Organization (1999) and Diabetes Health Organization (1999) and Diabetes UK (2000) endorsed the use of a fasting UK (2000) endorsed the use of a fasting plasma glucose test for screening purposes. plasma glucose test for screening purposes. Using this test, a diagnosis of diabetes Using this test, a diagnosis of diabetes can be made if symptoms are present and can be made if symptoms are present and a glucose value of more than 7.0 mmol/l a glucose value of more than 7.0 mmol/l is found (Table 1 ). The test must be peris found (Table 1 ). The test must be performed in an accredited laboratory using a formed in an accredited laboratory using a venous blood sample. In the absence of venous blood sample. In the absence of symptoms, symptoms, a second confirmatory blood test a second confirmatory blood test is required. is required. A value of more than 6.1 mmol/l A value of more than 6.1 mmol/l from a fasting sample suggests impaired from a fasting sample suggests impaired glucose tolerance or impaired fasting glucose tolerance or impaired fasting s1 0 7 s1 0 7 Although a random plasma glucose Although a random plasma glucose measurement would seem on the surface measurement would seem on the surface to be unreliable as a screening test, it does to be unreliable as a screening test, it does have certain merits. It is easy to perform, have certain merits. It is easy to perform, and if it shows a value of more than and if it shows a value of more than 11.1 mmol/l the patient has diabetes (Table  11 .1 mmol/l the patient has diabetes ( Table  1 ). The sensitivity of this test is reported 1). The sensitivity of this test is reported to be between 50% and 69%, with a to be between 50% and 69%, with a specificity of between 92% and 98% specificity of between 92% and 98% (Diabetes UK, 2002) . A glucose value of (Diabetes UK, 2002). A glucose value of 7.0-11.0 mmol/l requires follow-up, ideally 7.0-11.0 mmol/l requires follow-up, ideally with an OGTT. In 'unreliable' patients, with an OGTT. In 'unreliable' patients, fasting plasma glucose levels may be fasting plasma glucose levels may be elevated by a failure to fast; a random elevated by a failure to fast; a random plasma glucose test is, therefore, less likely plasma glucose test is, therefore, less likely to provide an overestimate, and this reduces to provide an overestimate, and this reduces the chances of a false positive result. the chances of a false positive result.
The HbA The HbA 1c 1c test provides an 'average test provides an 'average glucose value' for the preceding 6-8 weeks glucose value' for the preceding 6-8 weeks and is an excellent measure of glycaemic and is an excellent measure of glycaemic control. Unfortunately, its value as a control. Unfortunately, its value as a screening test is unproved. Estimates sugscreening test is unproved. Estimates suggest that test results above the 'normal' gest that test results above the 'normal' range provide sensitivities of between range provide sensitivities of between 35% and 98%, and specificities of between 35% and 98%, and specificities of between 79% and 100% when used for the purposes 79% and 100% when used for the purposes of screening (Diabetes UK, 2002 The question of who should be responsible for question of who should be responsible for screening is difficult to answer. Ideally, as screening is difficult to answer. Ideally, as the management of diabetes is increasingly the management of diabetes is increasingly becoming part of primary care, screening becoming part of primary care, screening for diabetes should be undertaken within for diabetes should be undertaken within community practice. Unfortunately, pricommunity practice. Unfortunately, primary health care services are already overmary health care services are already overstretched in many countries, and some stretched in many countries, and some primary care practices will be unable or unprimary care practices will be unable or unwilling to commit to offering structured willing to commit to offering structured screening programmes, even in high-risk screening programmes, even in high-risk groups.
groups.
An increasing number of pharmacists An increasing number of pharmacists are offering local screening services based are offering local screening services based upon a random blood glucose test (Diabetes upon a random blood glucose test (Diabetes UK, 2002) . This may be a matter of con-UK, 2002). This may be a matter of concern, not only for the reasons outlined cern, not only for the reasons outlined above, but also because pharmacists cannot above, but also because pharmacists cannot provide the appropriate clinical advice provide the appropriate clinical advice following a positive result. following a positive result.
Management strategies in diabetes Management strategies in diabetes
All patients with type 2 diabetes should be All patients with type 2 diabetes should be given lifestyle advice, particularly about given lifestyle advice, particularly about diet and exercise. Patients should be advised diet and exercise. Patients should be advised to: to:
(a) (a) decrease the energy and fat content of decrease the energy and fat content of their diet and increase fibre intake; their diet and increase fibre intake;
(b) (b) increase their intake of fruit and increase their intake of fruit and vegetables; vegetables;
(c) (c) eat complex rather than simple carboeat complex rather than simple carbohydrates, e.g. wholewheat bread rather hydrates, e.g. wholewheat bread rather than refined white bread; than refined white bread;
(d) (d) avoid sugary drinks; avoid sugary drinks;
(e) (e) exercise for at least 10-15 min per day. exercise for at least 10-15 min per day.
Lifestyle guidance is an integral comLifestyle guidance is an integral component of any management plan and ponent of any management plan and ultimately requires active patient participaultimately requires active patient participation and empowerment -a principle tion and empowerment -a principle endorsed by the National Institute for endorsed by the National Institute for Clinical Excellence (2003) . If lifestyle Clinical Excellence (2003) . If lifestyle changes alone in newly diagnosed, asympchanges alone in newly diagnosed, asymptomatic patients are unsuccessful after 3 tomatic patients are unsuccessful after 3 months, pharmacological agents are usually months, pharmacological agents are usually given as the next step. given as the next step.
Most diabetologists would consider the Most diabetologists would consider the biguanide metformin as first-line therapy, biguanide metformin as first-line therapy, particularly in patients who are overweight. particularly in patients who are overweight. The sulphonylureas (e.g. gliclazide, glibenThe sulphonylureas (e.g. gliclazide, glibenclamide, glipizide, glimepiride) are used as clamide, glipizide, glimepiride) are used as second-line agents, although they may be second-line agents, although they may be the first choice for those who are not overthe first choice for those who are not overweight or are unable to tolerate metformin. weight or are unable to tolerate metformin. The newer, rapid-acting insulin secretagoThe newer, rapid-acting insulin secretagogues (nateglinide and repaglinide) and the gues (nateglinide and repaglinide) and the thiazolidinediones (rosiglitazone and piothiazolidinediones (rosiglitazone and pioglitazone) are becoming increasingly popuglitazone) are becoming increasingly popular in patients unable to tolerate or failing lar in patients unable to tolerate or failing to benefit from first-line oral therapies. to benefit from first-line oral therapies. Most patients find themselves on a combiMost patients find themselves on a combination of oral therapies, and at least a quarnation of oral therapies, and at least a quarter of patients will go on to need insulin ter of patients will go on to need insulin injections at some stage. injections at some stage.
Assessing glycaemic control Assessing glycaemic control
There are two main approaches to assessing There are two main approaches to assessing glycaemic control; home blood glucose glycaemic control; home blood glucose monitoring, and the HbA monitoring, and the HbA 1c 1c test. Home test. Home blood glucose monitoring is performed by blood glucose monitoring is performed by the patient using a finger-prick spot of the patient using a finger-prick spot of blood and a simple home glucose meter, blood and a simple home glucose meter, which provides a result in around 20 s. which provides a result in around 20 s. Patients are encouraged to enter the glucose Patients are encouraged to enter the glucose readings into a diary; they are advised on readings into a diary; they are advised on the frequency of tests, and provided with the frequency of tests, and provided with a target blood glucose range by their doca target blood glucose range by their doctor. This enables patients to closely monitor tor. This enables patients to closely monitor and detect any changes in their blood and detect any changes in their blood glucose values, which should be reported glucose values, which should be reported to their primary care physician or diabetes to their primary care physician or diabetes specialist nurse. specialist nurse.
The 
I A B E T E S AND I T S P R E V EN T ION D I A B E T E S AND I T S P R E V E N T ION
currently patients with impaired glucose currently patients with impaired glucose tolerance are usually just given lifestyle tolerance are usually just given lifestyle advice. Blood glucose monitoring and advice. Blood glucose monitoring and measurement of HbA measurement of HbA 1c 1c are also routinely are also routinely undertaken in most of these patients. undertaken in most of these patients.
Pragmatic pathways of care
Pragmatic pathways of care in individuals with schizophrenia in individuals with schizophrenia All health care professionals should be All health care professionals should be aware that people with schizophrenia are aware that people with schizophrenia are at high risk of developing diabetes, and at high risk of developing diabetes, and timely screening and effective risk managetimely screening and effective risk management should be a priority for all these indiment should be a priority for all these individuals. Well-defined responsibilities and viduals. Well-defined responsibilities and good communication between mental good communication between mental health teams, primary care teams and diahealth teams, primary care teams and diabetes specialist services will be required to betes specialist services will be required to reduce the substantial burden of diabetes reduce the substantial burden of diabetes in people with schizophrenia. in people with schizophrenia.
Mental health teams should take some Mental health teams should take some responsibility for managing all general responsibility for managing all general health issues in their patients. This should health issues in their patients. This should include screening for diabetes, providing include screening for diabetes, providing education about healthy living, and involeducation about healthy living, and involving other specialist or primary care serving other specialist or primary care services when necessary (Fig. 1) . Mental vices when necessary (Fig. 1) . Mental health specialists should also be aware of health specialists should also be aware of local guidelines for the screening and local guidelines for the screening and management of diabetes, and if screening management of diabetes, and if screening programmes do not exist locally, they programmes do not exist locally, they should should consider establishing their own consider establishing their own programmes programmes in consultation with other in consultation with other stakeholders. stakeholders.
All patients at risk of developing diaAll patients at risk of developing diabetes -especially those with schizophrenia betes -especially those with schizophrenia or other serious mental illness -should or other serious mental illness -should receive lifestyle advice, including attention receive lifestyle advice, including attention to diet and exercise. Patients should be to diet and exercise. Patients should be encouraged to decrease their energy and encouraged to decrease their energy and fat intake, to increase their intake of fruit fat intake, to increase their intake of fruit and vegetables, and to exercise for at least and vegetables, and to exercise for at least 10-15 min per day. Patients taking anti-10-15 min per day. Patients taking antipsychotic medications should be given psychotic medications should be given clear guidance on how to avoid side-effects clear guidance on how to avoid side-effects such as weight gain, and should be such as weight gain, and should be screened regularly to detect any glucose screened regularly to detect any glucose abnormalities. Patients with schizophrenia need to Patients with schizophrenia need to understand the benefits of a healthy lifeunderstand the benefits of a healthy lifestyle to their overall well-being and future style to their overall well-being and future health. Physicians need to understand how health. Physicians need to understand how their patients live their lives, and whose their patients live their lives, and whose help they can enlist to change their patients' help they can enlist to change their patients' daily habits and to support the patient daily habits and to support the patient through any lifestyle adjustment. Motivating through any lifestyle adjustment. Motivating patients to take an interest in their own patients to take an interest in their own health may be a challenge -especially health may be a challenge -especially when dealing with a relatively asymptowhen dealing with a relatively asymptomatic condition such as diabetes. Pragmatic matic condition such as diabetes. Pragmatic pathways to care, aimed at reducing the pathways to care, aimed at reducing the risk of diabetes and preventing disease risk of diabetes and preventing disease progression in people with schizophrenia, progression in people with schizophrenia, will depend primarily on the individual's will depend primarily on the individual's circumstances. Recommended pathways circumstances. Recommended pathways for care in the most commonly encountered for care in the most commonly encountered circumstances are outlined below. circumstances are outlined below.
The non-diabetic patient with schizophrenia The non-diabetic patient with schizophrenia On the basis of guidelines outlined for the On the basis of guidelines outlined for the general population, it would seem sensible general population, it would seem sensible that all individuals with schizophrenia are that all individuals with schizophrenia are screened for diabetes on a regular basis. screened for diabetes on a regular basis. For the many reasons outlined above, it For the many reasons outlined above, it would be impractical to suggest the use of would be impractical to suggest the use of the OGTT or the fasting plasma glucose the OGTT or the fasting plasma glucose test to screen for diabetes in the population test to screen for diabetes in the population of people with schizophrenia, and we thereof people with schizophrenia, and we therefore recommend an annual random plasma fore recommend an annual random plasma glucose test as being the most appropriate glucose test as being the most appropriate screening method in this group. screening method in this group.
Enquiring about the symptoms of Enquiring about the symptoms of diabetes is an additional and straightdiabetes is an additional and straightforward way to identify patients requiring forward way to identify patients requiring further investigation. Simple questions further investigation. Simple questions ('Do you find yourself getting thirsty?' ('Do you find yourself getting thirsty?' 'Have you noticed an increase in the 'Have you noticed an increase in the amount you drink?' 'Do you get up to pass amount you drink?' 'Do you get up to pass water at night?' 'Do you need to take a water at night?' 'Do you need to take a drink to bed?') may be useful to identify drink to bed?') may be useful to identify some patients with diabetes. some patients with diabetes.
For drug-naıve patients starting an For drug-naïve patients starting an antipsychotic treatment or changing antiantipsychotic treatment or changing antipsychotic agent, it may be useful to perform psychotic agent, it may be useful to perform a baseline random or fasting plasma glua baseline random or fasting plasma glu- If any of the screening tests in a nonIf any of the screening tests in a nondiabetic patient with schizophrenia suggest diabetic patient with schizophrenia suggest the presence of diabetes or impaired glucose the presence of diabetes or impaired glucose tolerance, the patient should be referred to tolerance, the patient should be referred to their general practitioner or a diabetes their general practitioner or a diabetes specialist for a formal diagnosis. If the diagspecialist for a formal diagnosis. If the diagnosis is positive, the general practitioner nosis is positive, the general practitioner and/or diabetologist should coordinate the and/or diabetologist should coordinate the future management of diabetes and ensure future management of diabetes and ensure that the patient is reviewed regularly. The that the patient is reviewed regularly. The decision to continue, stop or change antidecision to continue, stop or change antipsychotic medication at this stage should psychotic medication at this stage should be taken only after consultation between be taken only after consultation between the psychiatrist and diabetologist or general the psychiatrist and diabetologist or general practitioner, and only after careful conpractitioner, and only after careful consideration of the benefits of the antisideration of the benefits of the antipsychotic agent. The primary goal is psychotic agent. The primary goal is always to ensure best control of the mental always to ensure best control of the mental illness; a change in antipsychotic mediillness; a change in antipsychotic medication might have adverse consequences cation might have adverse consequences for the mental health of the patient, and for the mental health of the patient, and would not normally be necessary. would not normally be necessary.
The patient with diabetes and schizophrenia The patient with diabetes and schizophrenia For patients with both diabetes and schizoFor patients with both diabetes and schizophrenia, good control of the mental illness phrenia, good control of the mental illness s1 0 9 s1 0 9 is also the priority. There are strong arguis also the priority. There are strong arguments to support the use of antipsychotic ments to support the use of antipsychotic agents in people with diabetes in order to agents in people with diabetes in order to aid compliance with both dietary and lifeaid compliance with both dietary and lifestyle advice and any drug treatment needed style advice and any drug treatment needed to manage the diabetes. Yu to manage the diabetes. Yu et al et al (2002) (2002) evaluated 22 patients with diabetes beginevaluated 22 patients with diabetes beginning atypical antipsychotic therapy, and ning atypical antipsychotic therapy, and found that blood glucose levels actually found that blood glucose levels actually improved in a significant number. Lindenimproved in a significant number. Lindenmayer mayer et al et al ( It would therefore seem appropriate that It would therefore seem appropriate that choice of medication for schizophrenia choice of medication for schizophrenia should be based purely upon efficacy, should be based purely upon efficacy, and not be influenced by potential and not be influenced by potential concerns over glucose metabolism (Citrome concerns over glucose metabolism (Citrome & Volavka, 2002 ). & Volavka, 2002 .
Patients with diabetes who are already Patients with diabetes who are already established on antipsychotic medication established on antipsychotic medication should be under the care of a diabetologist should be under the care of a diabetologist or general practitioner and, as for all other or general practitioner and, as for all other patients with diabetes, should be receiving patients with diabetes, should be receiving annual checks for metabolic control and annual checks for metabolic control and screening for complications. Patients screening for complications. Patients should be asked to continue with their should be asked to continue with their usual home blood glucose monitoring and usual home blood glucose monitoring and should inform their general practitioner/ should inform their general practitioner/ practice nurse or diabetes specialist nurse practice nurse or diabetes specialist nurse should there be should there be any change in their glucose any change in their glucose readings. Ideally, readings. Ideally, the mental health team the mental health team managing the schizophrenia should be kept managing the schizophrenia should be kept informed of any issues or concerns relating informed of any issues or concerns relating to glucose control. to glucose control.
DISCUSSION DISCUSSION
Patients with schizophrenia are at increased Patients with schizophrenia are at increased risk of developing type 2 diabetes as a result risk of developing type 2 diabetes as a result of an independent interaction between of an independent interaction between genetic and environmental factors. For this genetic and environmental factors. For this reason, all patients with schizophrenia reason, all patients with schizophrenia should be managed as a high-risk group should be managed as a high-risk group for the development of diabetes or impaired for the development of diabetes or impaired glucose tolerance and regularly screened glucose tolerance and regularly screened according to local guidelines. Achieving according to local guidelines. Achieving good control of the mental illness remains good control of the mental illness remains the treatment priority, and antipsychotic the treatment priority, and antipsychotic treatments should be selected on the basis treatments should be selected on the basis of their efficacy. of their efficacy.
Good communication between mental Good communication between mental health teams, primary care services and diahealth teams, primary care services and diabetes specialists will be the key to reducing betes specialists will be the key to reducing the inherent risk of developing diabetes in the inherent risk of developing diabetes in individuals with schizophrenia. Although individuals with schizophrenia. Although it is important for the psychiatrist to take it is important for the psychiatrist to take responsibility for reducing that risk, the responsibility for reducing that risk, the diabetologist and/or general practitioner diabetologist and/or general practitioner should be responsible for managing diabetes should be responsible for managing diabetes in patients with schizophrenia affected by in patients with schizophrenia affected by the condition. the condition. Poorly defined responsibilities and complex communication channels may preclude the multidisciplinary approach needed to manage diabetes risk successfully in patients the multidisciplinary approach needed to manage diabetes risk successfully in patients with schizophrenia. with schizophrenia.
APPENDIX APPENDIX
